» Articles » PMID: 29257290

Time-course Behavioral Features Are Correlated with Parkinson's Disease‑associated Pathology in a 6-hydroxydopamine Hemiparkinsonian Rat Model

Overview
Journal Mol Med Rep
Specialty Molecular Biology
Date 2017 Dec 20
PMID 29257290
Citations 37
Authors
Affiliations
Soon will be listed here.
Abstract

Parkinson's disease (PD) is one of the most common neurodegenerative diseases. For decades, the unilateral 6‑hydroxydopamine (6‑OHDA) rat model has been employed to investigate the pathogenesis and therapy of PD. However, the behavior and associated pathological features of the model long term have not previously been described dynamically. In the present study, the unilateral model was established by 6‑OHDA injection in the striatum. The PD rat model was determined 2 weeks following surgery, according to the apomorphine (APO)‑induced rotations, cylinder, rotarod and open field tests. TH‑positive neurons and fibers in the substantia nigra pars compacta (SNpc) and striatum, respectively, and glial activation in the SNpc, determined by glial fibrillary acidic protein (GFAP) expression for astrocytes and CD11b (Mac1) expression for microglia, were detected by immunohistological staining. Correlation analysis was performed to understand the association between PD‑associated behavior and pathology. The behavioral impairment progressively deteriorated during the process of experiment. In addition, the decrease in TH‑positive neurons was associated with an increase in GFAP‑ and Mac1‑positive cells in the SNpc. Linear regression analysis indicated the association between behavioral and pathological changes. The results of the present study indicate that the APO‑induced rotation, cylinder and rotarod tests are all sensitive and reliable strategies to predict the loss of TH+ neurons. These results provide a potential intervention time‑point and a comprehensive evaluation index system for assessment of PD therapeutic strategies using the hemiparkinsonian rat.

Citing Articles

Challenges and Opportunities in Exploring Non-Motor Symptoms in 6-Hydroxydopamine Models of Parkinson's Disease: A Systematic Review.

Prates-Rodrigues M, Schweizer B, de Paula Gomes C, Ribeiro A, Padovan-Neto F, Masini D J Neurochem. 2025; 169(2):e70008.

PMID: 39901598 PMC: 11791392. DOI: 10.1111/jnc.70008.


Targeting ferroptosis with the lipoxygenase inhibitor PTC-041 as a therapeutic strategy for the treatment of Parkinson's disease.

Minnella A, McCusker K, Amagata A, Trias B, Weetall M, Latham J PLoS One. 2024; 19(9):e0309893.

PMID: 39292705 PMC: 11410249. DOI: 10.1371/journal.pone.0309893.


Neuroprotective effects of L-Dopa-modified zinc oxide nanoparticles on the rat model of 6-OHDA-ınduced Parkinson's disease.

Yeni Y, Genc S, Sait Ertugrul M, Nadaroglu H, Gezer A, Mendil A Sci Rep. 2024; 14(1):19077.

PMID: 39154054 PMC: 11330516. DOI: 10.1038/s41598-024-69324-4.


Neuroprotective effects of tea bioactives in Parkinson's disease: proof-of-concept.

Lopes L, da Silva Barroso S, Caldas J, Vasconcelos P, Canuto K, Dariva C J Tradit Complement Med. 2024; 14(4):435-445.

PMID: 39035688 PMC: 11259708. DOI: 10.1016/j.jtcme.2024.01.003.


Transdermal delivery of resveratrol loaded solid lipid nanoparticle as a microneedle patch: a novel approach for the treatment of Parkinson's disease.

Bandiwadekar A, Jose J, Gopan G, Augustin V, Ashtekar H, Khot K Drug Deliv Transl Res. 2024; 15(3):1043-1073.

PMID: 38949746 DOI: 10.1007/s13346-024-01656-0.


References
1.
Yuan H, Li B, Xu J, Wang Y, He Y, Zheng Y . Tenuigenin protects dopaminergic neurons from inflammation-mediated damage induced by the lipopolysaccharide. CNS Neurosci Ther. 2012; 18(7):584-90. PMC: 6493587. DOI: 10.1111/j.1755-5949.2012.00347.x. View

2.
Landers M, Kinney J, van Breukelen F . Forced exercise before or after induction of 6-OHDA-mediated nigrostriatal insult does not mitigate behavioral asymmetry in a hemiparkinsonian rat model. Brain Res. 2013; 1543:263-70. DOI: 10.1016/j.brainres.2013.10.054. View

3.
Marti M, James C, Oo T, Kelly W, Burke R . Early developmental destruction of terminals in the striatal target induces apoptosis in dopamine neurons of the substantia nigra. J Neurosci. 1997; 17(6):2030-9. PMC: 6793754. View

4.
Jackson-Lewis V, Blesa J, Przedborski S . Animal models of Parkinson's disease. Parkinsonism Relat Disord. 2011; 18 Suppl 1:S183-5. DOI: 10.1016/S1353-8020(11)70057-8. View

5.
Redgrave P, Vautrelle N, Reynolds J . Functional properties of the basal ganglia's re-entrant loop architecture: selection and reinforcement. Neuroscience. 2011; 198:138-51. DOI: 10.1016/j.neuroscience.2011.07.060. View